Catherijne A. J. Knibbe
Leiden University
282 Papers
849 Citations
Catherijne A. J. Knibbe is an academic researcher from Leiden University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 49, co-authored 242 publications. Previous affiliations of Catherijne A. J. Knibbe include Erasmus University Medical Center & Utrecht University.
Chat about Author
Papers
Supervised Multidimensional Item Response Theory Modeling of Pediatric Iatrogenic Withdrawal Symptoms
Sebastiaan C. Goulooze,Erwin Ista,Monique van Dijk,Thomas Hankemeier,Dick Tibboel,Catherijne A. J. Knibbe,Elke H. J. Krekels +6 more
- 15 Oct 2019
TL;DR: Regular IRT modeling of pediatric iatrogenic withdrawal symptom data is compared with two new analysis approaches in which the latent variable is guided towards the condition of interest using numerical withdrawal severity scored by nurses as a “supervising variable:” supervised IRT (sIRT) and supervised multi‐dimensional (smIRT) modelling.
7
Remifentanil versus fentanyl during cardiac surgery on the incidence of chronic thoracic pain (REFLECT): study protocol for a randomized controlled trial
Sjoerd de Hoogd,Sabine J.G.M. Ahlers,Eric P.A. van Dongen,Dick Tibboel,Albert Dahan,Catherijne A. J. Knibbe,Catherijne A. J. Knibbe +6 more
TL;DR: The influence of perioperative remifentanil on long-term pain outcomes for cardiac patients in a prospective randomized trial is determined and may be used to optimize peri operative analgesia techniques and, thereby, improve quality of life after cardiac surgery.
7
Treatment of pulmonary embolism in an extremely obese patient.
Jeroen Diepstraten,Simone van Kralingen,Repke J. Snijder,Christian M. Hackeng,Bert van Ramshorst,Catherijne A. J. Knibbe +5 more
TL;DR: This case demonstrates the successful use of a maximum dose of 28,000 anti-Xa international units of tinzaparin for an extremely obese patient with proven PE, instead of the accepted doses of 175 IU/kg, as bridge therapy to a coumarin.
7
Pediatric pharmacology: current efforts and future goals to improve clinical practice
TL;DR: As drug effects and safety are the result of both PK and pharmacodynamic processes and as developmental changes may occur in both processes, it is essential for PK studies to be followed-up by PD studies when dose- adjustments based on PKs alone have been proven insufficient.
7
Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis
Esther J. H. Janssen,Diane E. T. Bastiaans,Pyry A. J. Välitalo,Annemarie M. C. van Rossum,Evelyne Jacqz-Aigrain,Evelyne Jacqz-Aigrain,Hermione Lyall,Catherijne A. J. Knibbe,David M. Burger +8 more
TL;DR: Bodyweight best predicted the developmental changes in apparent lamivudine clearance and volume of distribution, and for children aged 5 months-18 years with a body weight <14 kg, the dose should be increased from 8 to 10 mg kg-1 day-1 if the adult target for AUC0-24h is aimed for.
7